An empirical analysis of the effects of clinical pharmacist participation in multidisciplinary treatment on the management of critically ill patients
临床药师参与多学科诊疗模式对危重患者管理效果的实证分析

摘要

目的 剖析临床药师参与多学科诊疗模式对危重患者管理效果的实证价值。方法 选取我院2025年1月-2025年12月收治的120例危重患者为研究对象（涵盖内科、妇科、产科、儿科、新生儿科危重病例），按照诊疗模式分为对照组与观察组，每组60例。对照组采用常规多学科诊疗模式，观察组采用临床药师全程参与的多学科诊疗模式（全程参与观察组妇科、产科、儿科、新生儿科NICU会诊，协助参与内科、康复科会诊）。对比两组患者用药合理性、不良反应发生率、住院时间、ICU停留时间、死亡率及抗菌药物使用相关指标。结果 观察组用药合理率为93.33%，显著高于对照组的76.67%（P＜0.05）；观察组药物不良反应发生率为6.67%，低于对照组的20.00%（P＜0.05）；观察组住院时间、ICU停留时间均短于对照组（P＜0.05）；两组死亡率比较，差异无统计学意义（P＞0.05）；观察组抗菌药物使用时长、细菌培养阳性率均低于对照组（P＜0.05）。结论 临床药师参与多学科诊疗模式可显著提升危重患者用药合理性，降低药物不良反应发生率，缩短住院及ICU停留时间，优化抗菌药物使用，尤其适用于我院妇科、产科、儿科、新生儿科（NICU）、内科危重患者的管理，贴合我院临床实际需求。

Abstract

Objective To analyze the empirical value of clinical pharmacist participation in multidisciplinary treatment on the management of critically ill patients.
Methods 120 critically ill patients admitted to our hospital from January 2025 to December 2025 were selected as the study subjects (covering critically ill cases from internal medicine, gynecology, obstetrics, pediatrics, and neonatology). They were divided into a control group and an observation group according to the treatment model, with 60 patients in each group. The control group adopted the conventional multidisciplinary treatment model, while the observation group adopted a multidisciplinary treatment model with full participation of clinical pharmacists (fully participating in consultations with gynecology, obstetrics, pediatrics, and the NICU of the neonatology department, and assisting in consultations with internal medicine and rehabilitation departments). The rationality of medication use, incidence of adverse reactions, length of hospital stay, length of stay in the ICU, mortality rate, and indicators related to antibiotic use were compared between the two groups.
Results The rational drug use rate in the observation group was 93.33%, significantly higher than 76.67% in the control group (P<0.05); the incidence of adverse drug reactions in the observation group was 6.67%, lower than 20.00% in the control group (P<0.05); the length of hospital stay and ICU stay in the observation group were shorter than those in the control group (P<0.05); there was no statistically significant difference in mortality between the two groups (P>0.05); the duration of antibiotic use and the positive rate of bacterial culture in the observation group were lower than those in the control group (P<0.05).
Conclusion   The participation of clinical pharmacists in the multidisciplinary treatment model can significantly improve the rationality of medication use in critically ill patients, reduce the incidence of adverse drug reactions, shorten the length of hospital stay and ICU stay, and optimize the use of antibiotics. It is particularly suitable for the management of critically ill patients in our hospital's gynecology, obstetrics, pediatrics, neonatal intensive care unit (NICU), and internal medicine departments, and aligns with our hospital's actual clinical needs.